Table 1.
Demographic and clinicopathological features of the study cases
| IFX group n=66 |
ADM group n=37 |
Total series n=103 |
||
|---|---|---|---|---|
| Gender, n (%) | Female | 30 (45.4) | 24 (64.8) | 54 (52.4) |
| Age, mean [±SD] | Years | 44.1 [14.6] | 43.2 [11.8] | 43.7 [13.6] |
| Weight, mean [±SD] | Kg | 70.4 [15.0] | 70.0 [15.7] | 70.2 [15.2] |
| IBD disease, n (%) | CD | 49 (74.2) | 31 (83.8) | 80 (77.7) |
| UC | 17 (25.8) | 6 (16.2) | 23 (22.3) | |
| mAb Naïve, n (%) | Yes | 54 (81.8) | 20 (54) | 74 (71.8) |
| Immunomodulator, n (%) | AZA | 23 (34.8) | 13 (35.1) | 36 (35.0) |
| MCP | 2 (3) | 1 (0.9) | 3 (2.9) | |
| MTX | 3 (4.5) | 2 (5.4) | 5 (4.9) | |
| None | 38 (57.5) | 21 (20.8) | 59 (57.3) | |
| Anti-TNF intensification | Positive | 23 (34.8) | 10 (27) | 33 (32.0) |
| Duration anti-TNF, mean [± SD] | Years | 4.2 [2.3] | 3.6 [1.6] | 4.0 [2.1] |
| Albumin, mean [± SD] | mg/dL | 3.9 [0.5] | 4.1 [0.4] | 4.0 [0.5] |
| C reactive protein, mean [± SD] | mg/dL | 0.9 [1.3] | 0.6 [0.6] | 0.8 [1.1] |
| TNF, mean [± SD] | pg/mL | 283.1 [516.6] | 442.6 [362.9] | 341.1 [471.0] |
| ADA production, n (%) | Positive | 11 (16.7) | 2 (5.4) | 13 (12.6) |
| FCGR3 V158F polymorphism, n (%) | FF | 21 (31.8) | 19 (51.4) | 40 (38.8) |
| FV | 33 (50.0) | 14 (37.8) | 47 (44.6) | |
| VV | 12 (18.2) | 4 (10.8) | 16 (15.5) | |
IFX: infliximab, ADA: adalimmab, SD: Standard deviation, CD: Crohn's disease, UC: Ulcerative colitis, AZA, Azacytidine, MCP: Mercaptopurine, MTX: Methotrextate, ADA: Anti-drug antibody